La tunisie Medicale - 2022 ; Vol 100 ( n°08 ) : 626-641
[ 454 times seen ]

Introduction. Although lung damages are among the leading causes of death from Rheumatoid Arthritis (RA), few studies have assessed the spirometric and plethysmographic data and profile of patients with RA, particularly those with Anti-Citrullinated Peptides Antibodies Positive (ACPA+).
Aim. To compare the spirometric and plethysmographic data and profile of RA patients ACPA+ and ACPA-.
Methods. This comparative pilot study was performed over a two-year period (2018-2019) in Algiers (Algeria). The study included two groups of RA non-smoker patients: 26 ACPA+ and 33 ACPA-.RA was diagnosed according to the ACR/EULAR 2010 RA classification criteria. Spirometry and plethysmography were performed. The following definitions were applied: Obstructive Ventilatory Impairment (OVI): FEV1/FVC z-score < -1.645; Restrictive Ventilatory Impairment (RVI): Total Lung Capacity (TLC) z-score< -1.645; Mixed Ventilatory Impairment (MVI): FEV1/FVC z-score < -1.645 and TLC z-score < -1.645; lung- hyperinflation: residual volume z-score > +1.645; Nonspecific Ventilatory Impairment (NSVI): FEV1z-score < -1.645, FVC z-score < -1.645, FEV1 /FVC z-score ≥ -1.645, and TLC z-score ≥ -1.645.
Results. The ACPA-group was older than the ACPA+ one by ~ 10 years (63±13 vs. 53±12 years, p=0.0025; respectively). The ACPA+ and ACPA-groups included comparative percentages of patients having RVI, MVI, and NSVI (23.1 vs. 45.5%, p=0.0745; 3.8 vs. 3.0%, p=0.8654; and 7.7 vs. 6.1%, p=0.8086; respectively). Compared to the ACPA- group, the ACPA+ group included a higher percentage of patients having OVI and lung-hyperinflation (9.1 vs. 38.5%, p=0.0069; 9.1 vs. 42.3%, p=0.0029; respectively).
Conclusion. Compared to the ACPA- group, the ACPA+ one had more lung-hyperinflation and OVI, and comparative percentages of RVI, MVI, and NSVI.

Key - Words
  1. Usenbo A, Kramer V, Young T, Musekiwa A. Prevalence of arthritis in Africa: A systematic review and meta-analysis. PLoS One 2015;10(8):e0133858.
  2. Kvien TK, Uhlig T, Ødegård S, Heiberg MS. Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann N Y Acad Sci 2006;1069:212-222.
  3. Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 2010;62(6):1583-1591.
  4. Isobe Y, Ito S, Matsuda T, Iwano S, Uchida A, Takahashi N, et al. Longitudinal changes in pulmonary function and respiratory impedance of rheumatoid arthritis. Respir Physiol Neurobiol 2019;261:1-8.
  5. Ben Fredj H, Ben Saad H, Mhaouech N, Bouajina I, Tabka Z, Rouatbi S. Pulmonary function in rheumatoid arthritis in a Tunisian population. Tunis Med 2013;91(4):248- 253.
  6. Agrawal A, Thyagarajan B, Ceniza S, Hasan Yusuf S. Interstitial lung disease of the UIP variant as the only presenting symptom of rheumatoid arthritis. Case Rep Pulmonol 2015;2015:205175.
  7. Prisco L, Moll M, Wang J, Hobbs BD, Huang W, Martin LW, et al. Relationship between rheumatoid arthritis and pulmonary function measures on spirometry in the UK biobank. Arthritis Rheumatol 2021;73(11):1994-2002.
  8. Zaccardelli A, Liu X, Ford JA, Cui J, Lu B, Chu SH, et al. Asthma and elevation of anti-citrullinated protein antibodies prior to the onset of rheumatoid arthritis. Arthritis Res Ther 2019;21(1):246.
  9. Cortet B, Perez T, Roux N, Flipo RM, Duquesnoy B, Delcambre B, et al. Pulmonary function tests and high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis 1997;56(10):596-600.
  10. Vergnenègre A, Pugnere N, Antonini MT, Arnaud M, Melloni B, Treves R, Bonnaud F. Airway obstruction and rheumatoid arthritis. Eur Respir J 1997;10(5):1072-1078.
  11. Perry E, Kelly C, Eggleton P, De Soyza A, Hutchinson D. The lung in ACPA-positive rheumatoid arthritis: an initiating site of injury? Rheumatology (Oxford) 2014;53(11):1940-1950.
  12. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006;65(7):845-851.
  13. Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson C, Grunewald J, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006;54(1):38-46.
  14. de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, Schreuder GM, Ewals JA, Terwiel JP, et al. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 2008;58(5):1293-1298.
  15. hurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008;67(7):917-925.
  16. Van der Woude D. Anti-citrullinated protein antibodies (ACPA) in rheumatoid arthritis: linking genetic predisposition to clinical outcome. Leiden University, Leiden: Department Reumatolog; 2012. Available from this URL: access/item%3A2898027/view (last access: October 15th 2022).
  17. Demoruelle MK, Weisman MH, Simonian PL, Lynch DA, Sachs PB, Pedraza IF, et al. Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arthritis Rheum 2012;64(6):1756-1761.
  18. Daha NA, Toes RE. Rheumatoid arthritis: Are ACPA-positive and ACPAnegative RA the same disease? Nat Rev Rheumatol 2011;7(4):202-203.
  19. Grosse J, Allado E, Roux C, Pierreisnard A, Couderc M, Clerc-Urmes I, et al. ACPA- positive versus ACPA-negative rheumatoid arthritis: two distinct erosive disease entities on radiography and ultrasonography. Rheumatol Int 2020;40(4):615-624.
  20. Slimani S, Ladjouze-Rezig A. Prevalence of rheumatoid arthritis in an urban population of Algeria: a prospective study. Rheumatology (Oxford) 2014;53(3):571-3.
  21. Mosrane Y, Bougrida M, Alloui AS, Martani M, Rouabah L, Bourahli MK, et al. Systemic inflammatory profile of smokers with and without COPD. Rev Pneumol Clin 2017;73(4):188-198.
  22. Nafti S, Taright S, El Ftouh M, Yassine N, Benkheder A, Bouacha H, et al. Prevalence of asthma in North Africa: the asthma insights and reality in the maghreb (AIRMAG) study. Respir Med 2009;103 Suppl 2:S2-11.
  23. Dayton CS, Schwartz DA, Sprince NL, Yagla SJ, Davis CS, Koehnke RK, et al. Low- dose methotrexate may cause air trapping in patients with rheumatoid arthritis. Am J Respir Crit Care Med 1995;151(4):1189-1193.
  24. Lataoui S, Belghali S, Zeglaoui H, Bouajina E, Ben Saad H. Submaximal aerobic capacity and quality of life of patients with rheumatoid arthritis. Rev Mal Respir 2017;34(1):74-85.
  25. Neogi T, Aletaha D, Silman AJ, Naden RL, Felson DT, Aggarwal R, et al. The 2010 American college of rheumatology/European league against rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum 2010;62(9):2582-2591.
  26. Van der Heijde D, van der Helm-van Mil AH, Aletaha D, Bingham CO, Burmester GR, Dougados M, et al. EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. Ann Rheum Dis 2013;72(4):479-481.
  27. Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38(1):44-48.
  28. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint disease activity score (DAS28) and European league against rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68(6):954-960.
  29. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of disease activity score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis 2007;66(3):407-409.
  30. Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959;2(5147):257-266.
  31. Tsai AG, Wadden TA. In the clinic: obesity. Ann Intern Med 2013;159(5):ITC3-1- ITC3-15; quiz ITC3-16.
  32. Bottiger LE, Svedberg CA. Normal erythrocyte sedimentation rate and age. Br Med J 1967;2(5544):85-87.
  33. Colombet I, Pouchot J, Kronz V, Hanras X, Capron L, Durieux P, et al. Agreement between erythrocyte sedimentation rate and C-reactive protein in hospital practice. Am J Med 2010;123(9):863 e7-13.
  34. Villar E, Lièvre M, Kessler M, Lemaître V, Alamartine E, Rodier M. Anemia normalization in patients with type 2 diabetes and chronic kidney disease: results of the NEPHRODIAB2 randomized trial. J Diabetes Complications 2011;25(4):237-243.
  35. Abramson N, Melton B. Leukocytosis: basics of clinical assessment. Am Fam Physician 2000;62(9):2053-2060.
  36. Van Zeben D, Hazes JM, Zwinderman AH, Cats A, van der Voort EA, Breedveld FC. Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis 1992;51(9):1029-1035.
  37. Cassani F, Bianchi FB, Lenzi M, Volta U, Pisi E. Immunomorphological characterisation of antinuclear antibodies in chronic liver disease. J Clin Pathol 1985;38(7):801-805.
  38. Marin GG, Cardiel MH, Cornejo H, Viveros ME. Prevalence of antinuclear antibodies in 3 groups of healthy individuals: blood donors, hospital personnel, and relatives of patients with autoimmune diseases. J Clin Rheumatol 2009;15(7):325-329.
  39. Coenen D, Verschueren P, Westhovens R, Bossuyt X. Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem 2007;53(3):498-504.
  40. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008;246(3):697-722.
  41. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005;26(2):319-338.
  42. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005;26(3):511- 522.
  43. Ketfi A, Gharnaout M, Ben Saad H. The plethysmographic reference equations established for adult natives of Eastern Algeria are not applicable to natives of Northern Algeria. Rev Mal Respir 2019;36(7):870-879.
  44. Ketfi A, Gharnaout M, Bougrida M, Ben Saad H. The multi-ethnic global lung initiative 2012 (GLI-2012) norms reflect contemporary adult’s Algerian spirometry. PLoS One 2018;13(9):e0203023.
  45. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 2012;40(6):1324-1343.
  46. Hall GL, Filipow N, Ruppel G, Okitika T, Thompson B, Kirkby J, et al. Official ERS technical standard: Global Lung Function Initiative reference values for static lung volumes in individuals of European ancestry. Eur Respir J 2021;57(3).
  47. Ketfi A, Ben Saad H. The global lung function initiative 2021 (GLI-2021) norms provide mixed results for static lung volumes (SLVs) in Algerian adults. Libyan J Med 2022;17(1):2059893.
  48. Ben Saad H. Interpretation of respiratory functional explorations of deficiency and incapacity in adult. Tunis Med 2020;98(11):797-815.
  49. Ben Saad H. Review of the current use of global lung function initiative norms for spirometry (GLI-2012) and static lung volumes (GLI-2021) in Great Arab Maghreb (GAM) countries and steps required to improve their utilization. Libyan J Med 2022;17(1):2031596.
  50. Stanojevic S, Kaminsky DA, Miller MR, Thompson B, Aliverti A, Barjaktarevic I, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J. 2022;60(1):2101499.
  51. Kammoun R, Ghannouchi I, Rouatbi S, Ben Saad H. Defining and grading an obstructive ventilatory defect (OVD): ‘FEV1/FVC lower limit of normal (LLN) vs. Z-score’ and ‘FEV1 percentage predicted (%pred) vs. Z-score’. Libyan J Med 2018;13(1):1487751.
  52. Serhier Z, Bendahhou K, Ben Abdelaziz A, Bennani MO. Methodological sheet n degrees 1: How to calculate the size of a sample for an observational study? Tunis Med 2020;98(1):1-7.
  53. Olejnik S, Algina J. Measures of effect size for comparative studies: applications, interpretations, and limitations. Contemp Educ Psychol 2000;25(3):241-286.
  54. Reynisdottir G, Karimi R, Joshua V, Olsen H, Hensvold AH, Harju A, et al. Structural changes and antibody enrichment in the lungs are early features of anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheumatol 2014;66(1):31-39.
  55. Ruiz-Esquide V, Gómara MJ, Peinado VI, Gómez Puerta JA, Barberá JA, Cañete Jde D, et al. Anti-citrullinated peptide antibodies in the serum of heavy smokers without rheumatoid arthritis. A differential effect of chronic obstructive pulmonary disease? Clin Rheumatol 2012;31(7):1047-1050.
  56. Perry E, Kelly C, de-Soyza A, Moullaali TJ, Eggleton P, Hutchinson DG. Natural history, disease characteristics and autoantibody positivity in patients with bronchiectasis and RA: is the lung an initiating site of autoimmunity in rheumatoid arthritis? Rheumatology 2013;52:i76-7.
  57. Kochbati S, Boussema F, Ben Miled M, Shili S, Chérif M, Ben Amor G, et al. Bronchiectasis in rheumatoid arthritis. High resolution computed pulmonary tomography. Tunis Med 2003;81(10):768-773.
  58. Bilgici A, Ulusoy H, Kuru O, Celenk C, Unsal M, Danaci M. Pulmonary involvement in rheumatoid arthritis. Rheumatol Int 2005;25(6):429-435.
  59. Van de Sande MG, de Hair MJ, van der Leij C, Klarenbeek PL, Bos WH,Smith MD, et al. Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis 2011;70(5):772-777.
  60. Huang S, He X, Doyle TJ, Zaccardelli A, Marshall AA, Friedlander HM, et al. Association of rheumatoid arthritis-related autoantibodies with pulmonary function test abnormalities in a rheumatoid arthritis registry. Clin Rheumatol 2019;38(12):3401- 3412.
  61. Fischer A, Solomon JJ, du Bois RM, Deane KD, Olson AL, Fernandez-Perez ER, et al. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med 2012;106(7):1040-1047.
  62. Inui N, Enomoto N, Suda T, Kageyama Y, Watanabe H, Chida K. Anticyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. Clin Biochem 2008;41(13):1074-1077.
  63. Kelly C, Chan C, Ahmad Y. RA-related interstitial lung disease: which factors predict its development? Rheumatology 2013;52:i75.
  64. Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med 2012;106(11):1591-1599.
  65. Wilsher M, Voight L, Milne D, Teh M, Good N, Kolbe J, et al. Prevalence of airway and parenchymal abnormalities in newly diagnosed rheumatoid arthritis. Respir Med 2012;106(10):1441-1446.
  66. Ben Saad H, Ben Amor L, Ben Mdalla S, Ghannouchi I, Ben Essghair M, Sfaxi R, et al. The importance of lung volumes in the investigation of heavy smokers. Rev Mal Respir 2014;31(1):29-40.
  67. Perez T, Guenard H. Evaluation and follow up of hyperinflation in COPD. Rev Mal Respir 2009;26(4):381-393; quiz 478, 482.
  68. O’Donnell D E. Dynamic lung hyperinflation and its clinical implication in COPD. Rev Mal Respir 2008;25(10):1305-1318.
  69. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350(26):2645-2653.
  70. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26(5):948-968.
  71. Laveneziana P, Albuquerque A, Aliverti A, Babb T, Barreiro E, Dres M, et al. ERS statement on respiratory muscle testing at rest and during exercise. Eur Respir J 2019;53(6):1801214.
  72. Lee G, Walser TC, Dubinett SM. Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer. Curr Opin Pulm Med 2009;15(4):303-307.
  73. Newkirk MM, Mitchell S, Procino M, Li Z, Cosio M, Mazur W, et al. Chronic smoke exposure induces rheumatoid factor and anti-heat shock protein 70 autoantibodies in susceptible mice and humans with lung disease. Eur J Immunol 2012;42(4):1051- 1061.
  74. Yang DH, Tu CC, Wang SC, Wei CC, Cheng YW. Circulating anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis and chronic obstructive pulmonary disease. Rheumatol Int 2014;34(7):971-977.
  75. Zaccardelli A, Liu X, Ford JA, Cui J, Lu B, Chu SH, et al. Elevated anticitrullinated protein antibodies prior to rheumatoid arthritis diagnosis and risks for chronic obstructive pulmonary disease or asthma. Arthritis Care Res (Hoboken) 2021;73(4):498-509.
  76. Park WH, Kim SS, Shim SC, Song ST, Jung SS, Kim JH, et al. Visual assessment of chest computed tomography findings in anti-cyclic citrullinated peptide antibody positive rheumatoid arthritis: Is it associated with airway abnormalities? Lung 2016;194(1):97-105.
  77. Grönwall C, Liljefors L, Bang H, Hensvold AH, Hansson M, MathssonAlm L, et al. A comprehensive evaluation of the relationship between different IgG and IgA anti- modified protein autoantibodies in rheumatoid arthritis. Front Immunol 2021;12:627986.
  78. Olive JT, Jr., Hyatt RE. Maximal expiratory flow and total respiratory resistance during induced bronchoconstriction in asthmatic subjects. Am Rev Respir Dis 1972;106(3):366-376.
  79. Iyer VN, Schroeder DR, Parker KO, Hyatt RE, Scanlon PD. The nonspecific pulmonary function test: longitudinal follow-up and outcomes. Chest 2011;139(4):878-886.
  80. Wan ES, Fortis S, Regan EA, Hokanson J, Han MK, Casaburi R, et al. Longitudinal phenotypes and mortality in preserved ratio impaired spirometry in the COPDGene study. Am J Respir Crit Care Med 2018;198(11):1397-1405.
  81. Fortis S, Comellas A, Kim V, Casaburi R, Hokanson JE, Crapo JD, et al. Low FVC/TLC in preserved ratio impaired spirometry (PRISm) is associated with features of and progression to obstructive lung disease. Sci Rep 2020;10(1):5169.
  82. Marott JL, Ingebrigtsen TS, Çolak Y, Vestbo J, Lange P. Trajectory of preserved ratio impaired spirometry: natural history and long-term prognosis. Am J Respir Crit Care Med 2021;204(8):910-920.
  83. Aaron SD, Dales RE, Cardinal P. How accurate is spirometry at predicting restrictive pulmonary impairment? Chest 1999;115(3):869-873.
  84. Hyatt RE, Cowl CT, Bjoraker JA, Scanlon PD. Conditions associated with an abnormal nonspecific pattern of pulmonary function tests. Chest 2009;135(2):419- 424.
  85. Mascha EJ, Vetter TR. Significance, errors, power, and sample size: The blocking and tackling of statistics. Anesth Analg 2018;126(2):691-698.
  86. Kammoun R, Ben Saad H. From deficiency to handicap in the respiratory field: lung function tests (LFT) norms and quality of life (QOL) questionnaires validated for the Tunisian population. Tunis Med 2020;98(5):378-395.
  87. Knaz H, Anane I, Guezguez F, Prefaut C, Ben Saad H. Applicability of the Arabic version of the French quality of life’ (QOL) questionnaire (VQ11) in Tunisian patients with chronic obstructive pulmonary disease. Rev Mal Respir 2020;37(9):699-709.
E-mail :
Password :
Remember Me Forgot password? Sign UP
Keywords most used
Tunisia treatment Child diagnosis surgery prognosis Children epidemiology Risk factors Crohn’s disease prevalence Breast cancer obesity screening Cancer
Sign up to receive our newsletter
E-mail :
Stay in Touch
Join Us! !